|
GenVec Technology Demonstrates Selective Anti-Cancer Activity |
|
|
|
20 Sep 2007 |
GenVec, Inc. announced today the publication of pre-clinical research demonstrating the selective delivery of TNF-alpha to tumors
GAITHERSBURG, MD, USA | September 20, 2007 | GenVec, Inc. (Nasdaq: GNVC) announced today the publication of pre-clinical research demonstrating the selective delivery of TNF-alpha to tumors. Combining a new, targeted adenovector with selective regulation of gene expression achieved a high degree of anti-tumor activity and selectivity in animal models of disseminated ovarian cancer.
The paper, Experimental Treatment Of Ovarian Cancers By Adenovirus Vectors Combining Receptor Targeting And Selective Expression Of Tumor Necrosis Factor, authored by GenVec scientist Selva R. Murugesan, Ph.D., appears in the October issue of the International Journal of Oncology, (31: 813-822, 2007). It describes how GenVec technology was used to modify the structure of adenovectors to control both their ability to selectively bind to ovarian cancer cells and enhance the expression of TNF alpha protein in tumor cells. Results demonstrated that the modified adenovector induced anti-tumor responses and limited expression of TNF in normal tissue. These highly selective adenovectors may provide the basis for a potentially safe and effective treatment for cancers of the peritoneal space including ovarian and stomach cancers.
“Our new generation adenovector uses a combination of technologies which enable targeted delivery of our drug specifically to the tumor and control of gene expression within the tumor cells, avoiding toxicity in surrounding healthy tissue. This is an excellent example of how GenVec’s technology can be applied to provide new treatment strategies,” commented C. Richter King, Ph.D., GenVec’s Senior Vice President of Research.
About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec’s lead product, TNFerade™ is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza.
Additional information about GenVec is available at www.genvec.com and in the company’s various filings with the Securities and Exchange Commission.
SOURCE: GENVEC
|
